Now, the programme has expanded. Galapagos is adding new candidates to the portfolio, which aims to target different types of cystic fibrosis and therefore cover 90% of the patients.
In order to create this broad spectrum therapy, the two companies are developing a triple combination therapy targeting CFTR, the malfunctioning protein that causes cystic fibrosis.
Triple combination therapies have shown good preclinical results, including in vitro restoration of healthy activity levels in human bronchial epithelial (HBE) cells of patients with the F508del mutation – the most common genetic mutations leading to cystic fibrosis.
It is expected that clinical trial for this therapy will take place in 2017. Reflecting the ‘upgrade’ of the collaboration, Galapagos’ potential milestones’ payments have gone up from €300M to €520M.
It looks definite: AbbVie-Galapagos collaboration for cystic fibrosis is here to stay.
Featured image credit: Galapagos (CC 2.0 pantxorana)
Figure 1 credit: Quintana-Gallego et al. (2013) CFTR Protein Repair Therapy in Cystic Fibrosis. Arch Bronconeumol (doi: 10.1016/j.arbr.2014.03.002)
Let's Continue The Conversation
Feel free to send us comments about this article to email@example.com and/or comment on that article on social media.